Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05057429
Other study ID # 20210621
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 11, 2021
Est. completion date August 1, 2024

Study information

Verified date February 2024
Source University of Miami
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to test if the use of a bioelectric dressing can improve healing after a surgical procedure called de-roofing.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date August 1, 2024
Est. primary completion date August 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults 18 years old and older. - Have diagnosis of HS confirmed by a dermatologist - Have at least two ancillary tunnels in separate anatomical sites - Able to provide informed consent Exclusion Criteria: - Individuals who are not yet adults - Subject is allergic to any of the materials and dressings involved in the procedures - Women known to be pregnant - Prisoners - Subjects, who in the opinion of the PI, cannot comply with hope application of the treatment

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Procellera Bioelectric Dressing
Procellera is single layer, broad-spectrum antimicrobial wound dressing. Embedded in the dressing are microcell batteries made of elemental silver and zinc applied in a dot-matrix pattern. The bioelectric dressing will be applied to surgical site wound with a hydrogel.
Other:
Standard Gauze Dressing
Standard of care non-adherent gauze dressing will be applied to surgical site with vaseline.

Locations

Country Name City State
United States University of Miami Miami Florida

Sponsors (2)

Lead Sponsor Collaborator
University of Miami Vomaris Innovations

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Healing Rate The healing rate of post-surgical wounds will be reported as the area reduction in cm^2/per day. Up to 8 weeks
Secondary Average time to complete healing The average time, measured in days, to complete healing as assessed by treating physician will be reported Up to 8 weeks
Secondary Number of subjects with complete healing The number of subjects with complete post-surgical site healing, as evaluated by treating physician, will be reported. Up to 8 weeks
Secondary Number of subjects with nodule and/or tunnel recurrence The number of subjects with nodule and/or tunnel recurrence, as evaluated by treating physician, will be reported. Up to 8 weeks
Secondary Average pain as assessed by the Numerical Rating Scale (NRS) The average pain will be measured using the NRS with scores ranging from 0-10 with the higher score indicating more severe pain. Up to 8 weeks
Secondary Number of subjects with tenderness at surgical sites The number of subjects with tenderness at surgical sites, as evaluated by treating physician, will be reported. Up to 8 weeks
Secondary Quality of post-surgical scars as measured by the Hurley Stage score The Hurley score is staged as: 1 (single or multiple abscesses without sinus tract formation or scarring); 2 (recurrent abscesses with one or more sinus tracts and scarring widely separated by normal skin); 3 (diffuse involvement with multiple sinus tracts and no intervening normal skin) Up to 8 weeks
Secondary Amount of exudate at surgical site The amount of exudate at surgical site will be evaluated using a 5 point Likert scale from 0 (Dry) to 4 (Leaking). Up to 8 weeks
Secondary Shoulder range of motion Shoulder range of motion will be measured using a goniometer Up to 8 weeks
Secondary Number of dressings used through to healing day The number of dressings used through to healing day will be reported Up to 8 weeks
Secondary Pain after procedure as assessed by the NRS The average pain will be measured using the NRS with scores ranging from 0-10 with the higher score indicating more severe pain. Day 2 (24 hours post procedure)
Secondary Days of work lost Participants reported days of work lost due to the procedure will be reported Up to 8 weeks
Secondary Change in Quality of Life as measured by the DLQI Dermatology Life Quality Index (DLQI) has a total score ranging from 0 to 30 with the lower score indicating higher health related quality of life Baseline, Up to 8 weeks
Secondary Tissue analysis of microbiome As measured by quantitative 16s rDNA Polymerase Chain Reaction for bacterial enumeration from punch biopsy and biofilm samples. Up to 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT02904902 - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Phase 3
Completed NCT03628924 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2
Not yet recruiting NCT05531747 - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa N/A
Recruiting NCT06028230 - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Completed NCT03275870 - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Phase 1/Phase 2
Completed NCT03248531 - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Phase 2
Withdrawn NCT04100083 - Spironolactone for Hidradenitis Suppurativa Phase 4
Completed NCT00329823 - Etanercept in Hidradenitis Suppurativa Phase 2
Recruiting NCT05710393 - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed NCT04019041 - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa Phase 2
Completed NCT05286567 - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. Phase 1
Withdrawn NCT03929835 - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Phase 2
Terminated NCT04325607 - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa N/A
Terminated NCT03238469 - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa N/A
Completed NCT04449354 - HidraWear AX HS Study N/A
Recruiting NCT06123429 - Mindfulness in Hidradenitis Suppurativa N/A
Recruiting NCT05934825 - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa Phase 1/Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT06046729 - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Recruiting NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome Phase 2